Biomed Lublin has started production of the first batch of a Covid-19 medication. The medicine will be based on plasma from people who have been infected with coronavirus and have recovered. This remedy, subsequently, will be used to struggle against the infection in new patients, significantly enhancing the body’s chances of fighting the virus.
Biomed is to produce about 3,000 ampoules of the cure in the first batch. It will be administered to patients in the Department of Infectious Diseases at the Independent Public Hospital No. 1 (PSK 1) in Lublin, where clinical trials will be conducted. The studies will last about four months. Afterwards, the drug can be submitted for registration and be distributed. The head of the Department of Infectious Diseases at Independent Clinical Hospital No. 1, professor Krzysztof Tomasiewicz, stated dispensing convalescent plasma to patients has brought about positive results, so a drug made from blood plasma should be effective.
This production is the solution to the health problems coronavirus has caused. Moreover, vaccines, as the world is discovering, can take years to develop. The success from Biomed Lublin follows the company’s 75-year history of dealing with epidemics and pandemics.
